The UK leaving the EU is not the end of cooperation. Talks are ongoing to determine how the two will work together on anything from trade to transport and the fight against crime.
The EU and the UK face many of the same challenges such as climate change and police cooperation and have much to gain from working together on these issues.
The Withdrawal Agreement, which has been ratified by both parties, covers the protection of the rights of EU citizens in the UK and UK citizens living in other parts of the EU, the UK’s financial commitments undertaken as a member state, as well border issues (especially between the UK and the Republic of Ireland) and this needs to be implemented in full.
Future relations will be part of a separate agreement, which is currently being negotiated on the basis of the political declaration that was approved and ratified by both parties.
In a resolution adopted on 12 February, MEPs called for a comprehensive agreement that includes a level playing field to be guaranteed through robust commitments and an agreement on fisheries.
On 29 May, David McAllister, chair of Parliament’s UK Coordination Group, said in a statement: “Parliament will not consent to an agreement that does not include provisions on level playing field, fundamental rights, robust governance and a stable framework for fisheries.
“It also considers the full implementation of the Withdrawal Agreement, co-signed by the UK Prime Minister, to be crucial.”
Members of the foreign affairs and trade committees reiterated their overwhelming support for the EU position in the talks between the EU and the UK on their future relationship on 12 June. All MEPs will vote on the draft resolution during the plenary session on 17-19 June.
The committee votes came ahead of a conference on the ongoing talks on 15 June with UK Prime Minister Boris Johnson, European Council President Charles Michel and Commission President Ursula Von der Leyen and the participation of Parliament President David Sassoli. After the conference, they issued a joint statement.
What the future relations agreement will cover
The issues in any agreement on future relations range from the exchange of goods and services to the environment, research, education and so on.
One of the key negotiations will concern the conditions and principles for future trade, including the questions of possible tariffs, product standards, a level-playing field, fisheries, the respect of fundamental rights and how to resolve disputes.
Citizens’ rights are protected by the withdrawal agreement. EU citizens in the UK and Brits in the EU have the right to continue living and working where they are now. This topic will remain a key concern for the European Parliament, for example regarding freedom of movement and health coverage for EU citizens in the UK. MEPs are following closely how the withdrawal agreement is being implemented.
Under the withdrawal agreement, there is a transition period until the end of December 2020. During the transition period, the UK has access to the single market and is subject to EU legislation, although it is no longer be able to shape new EU laws.
The aim is to conclude talks before the end of the transition period. The transition period can be extended upon request once, but the decision to do so must be taken before 1 July.
If no agreement is reached by the end of the transition period, the UK will trade with the EU under World Trade Organization rules.
How the negotiations work
Former commissioner Michel Barnier leads the negotiations on behalf of the EU, based on political guidelines issued by the European Council. Barnier also led negotiations on the withdrawal agreement.
MEPs are able to influence negotiations by adopting resolutions setting out the Parliament’s position. Parliament set up a UK contact group, led by German EPP member David McAllister, who is the chair of the foreign affairs committee, to liaise with EU negotiator Barnier and coordinate with parliamentary committees that are involved.
Any agreement can only enter into force if it is approved by the European Parliament and the Council. Unlike the withdrawal agreement, it is also possible that the agreement on future relations will also have to be approved by national parliaments if it refers to competences the EU shares with member states. It will also need to be approved by the UK.
Coronavirus: Commission unveils EU vaccines strategy
Today, to help protect people everywhere, the European Commission is presenting a European strategy to accelerate the development, manufacturing and deployment of vaccines against COVID-19. An effective and safe vaccine against the virus is our best bet to achieve a permanent solution to the pandemic. Time is of the essence. Every month gained in finding such a vaccine saves lives, livelihoods and billions of euros. Today’s strategy proposes a joint EU approach and builds on the mandate received from EU health ministers.
European Commission President Ursula von der Leyen said: “This is a moment for science and solidarity. Nothing is certain, but I am confident that we can mobilise the resources to find a vaccine to beat this virus once and for all. We must be ready to manufacture and deploy such a vaccine across Europe and the world. This vaccine will be a breakthrough in the fight against the coronavirus, and a testament to what partners can achieve when we put our minds, research and resources together. The European Union will do all in its power to ensure that all peoples of this world have access to a vaccine, irrespective of where they live.”
Commissioner for Health and Food Safety Stella Kyriakides said: “Working together will increase our chances of securing access to a safe and effective vaccine at the scale we need and as quickly as possible. It will ensure fair and equitable access for all across the EU and globally, thus offering the best opportunity of finding a permanent exit strategy from the COVID-19 crisis. This is the EU at its best: pooling resources, joining efforts, bringing tangible results to the everyday lives of people. No one is safe until everyone is safe and we will leave no stones unturned in our efforts to protect EU and global citizens.”
Vaccine development is a complex and lengthy process. With today’s strategy, the Commission will support efforts to accelerate the development and availability of safe and effective vaccines in a timeframe between 12 and 18 months, if not earlier. Delivering on this complex undertaking requires running clinical trials in parallel with investing in production capacity to be able to produce millions, or even billions, of doses of a successful vaccine. The Commission is fully mobilised to support the efforts of vaccine developers in their endeavour.
This is not a European challenge, but a global one. The European Union will not be safe until the entire world has access to a vaccine, and as such, the EU and its Member States have both a responsibility and an interest to make a vaccine universally available.
An important step towards joint action between Member States has already been taken in the formation of an inclusive vaccine Alliance by France, Germany, Italy, and the Netherlands. The EU Vaccine Strategy will implement a joint approach going forward.
The strategy has the following objectives:
- Ensuring the quality, safety and efficacy of vaccines.
- Securing swift access to vaccines for Member States and their populations while leading the global solidarity effort.
- Ensuring equitable access to an affordable vaccine as early as possible.
The EU strategy rests on two pillars:
- Securing the production of vaccines in the EU and sufficient supplies for its Member States through Advance Purchase Agreements with vaccine producers via the Emergency Support Instrument. Additional financing and other forms of support can be made available on top of such agreements.
- Adapting the EU’s regulatory framework to the current urgency and making use of existing regulatory flexibility to accelerate the development, authorisation and availability of vaccines while maintaining the standards for vaccine quality, safety and efficacy.
Advance Purchase Agreements
In order to support companies in the swift development and production of a vaccine, the Commission will enter into agreements with individual vaccine producers on behalf of the Member States. In return for the right to buy a specified number of vaccine doses in a given timeframe, the Commission will finance part of the upfront costs faced by vaccines producers. This will take the form of Advance Purchase Agreements. Funding provided will be considered as a down-payment on the vaccines that will actually be purchased by Member States.
The related funding will come from a significant part of the €2.7 billion Emergency Support Instrument. Additional support will be available through loans from the European Investment Bank.
When taking the financing decision on what vaccines to support, the following non-exhaustive criteria will be taken into account, including: soundness of scientific approach and technology used, speed of delivery at scale, cost, risk sharing, liability, coverage of different technologies, early engagement with EU regulators, global solidarity, and capacity to supply through development of production capacity within the EU.
There is always a risk that supported candidates fail during clinical trials. This Strategy is therefore similar to an insurance policy, by transferring some of the risks from industry to public authorities in return for assuring Member States of equitable and affordable access to a vaccine, should one become available.
A flexible and robust regulatory process
Regulatory processes will be flexible but remain robust. Together with the Member States and the European Medicines Agency, the Commission will make the greatest use of existing flexibilities in the EU’s regulatory framework to accelerate the authorisation and availability of successful vaccines against COVID-19. This includes an accelerated procedure for authorisation, flexibility in relation to labelling and packaging, and a proposal to provide temporary derogations from certain provisions of the GMO legislation to speed up clinical trials of COVID-19 vaccines and medicines containing genetically modified organisms.
The EU is contributing to the global effort for universal testing, treatment and vaccination by mobilising resources through international pledging and by joining forces with countries and global health organisations through the Access To Covid-19 Tools (ACT) Accelerator collaborative framework. The Global Coronavirus Response pledging campaign raised €9.8 billion by the end of May 2020. A second step is underway in partnership with Global Citizen and other governmental and non-governmental partners, culminating in a global pledging summit on 27 June.
The European Commission is committed to the principle of universal, equitable and affordable access to vaccines, especially for the most vulnerable countries. It is ready to explore with international partners if a significant number of countries would agree to pool resources for jointly reserving future vaccines from companies for themselves as well as for low and middle-income countries at the same time. The high-income countries could act as an inclusive international buyers’ group, thus accelerating the development of safe and effective vaccines and maximise access to them for all who need it across the world.